ATA-3271

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameATA-3271

Drug Alias NameATA-3271

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsSolid tumoursMesothelioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesAtara Biotherapeutics Inc Memorial Sloan Kettering Cancer Center Bayer AG

Inactive CompaniesN/A

Active IndicationsSolid tumoursMesothelioma

Inactive IndicationsN/A

Other Information

ATC CodeN/A